Ascentage Pharma to Present 17 Clinical Advances at EHA2026 Congress

summarizeSummary

Ascentage Pharma announced it will present 17 clinical advances for its core drug candidates, Olverembatinib and Lisaftoclax, at the upcoming European Hematology Association Congress.

check_boxKey Events

• Major Clinical Data Presentation

  Ascentage Pharma will present 17 clinical advances, including 8 poster presentations, at the 31st European Hematology Association (EHA2026) Congress from June 11-14, 2026.

• Key Drug Candidates Featured

  The presentations will feature data from ongoing clinical studies for Olverembatinib (HQP1351), China's first approved third-generation BCR-ABL inhibitor, and Lisaftoclax (APG-2575), the first approved China-developed Bcl-2 selective inhibitor.

• Updated Efficacy and Phase 3 Results

  Abstracts include updated efficacy and safety data for Olverembatinib in chronic myeloid leukemia (CML), efficacy in CML with prior resistance, and updated results from the global registrational Phase 3 POLARIS-1 study for Olverembatinib in newly diagnosed Ph+ acute lymphoblastic leukemia (ALL).

auto_awesomeAnalysis

Ascentage Pharma will present 17 clinical advances, including updated efficacy and safety data for its key assets Olverembatinib and Lisaftoclax, at the European Hematology Association (EHA) Congress in June. This significant number of presentations, particularly the updated Phase 3 results for Olverembatinib and data for Lisaftoclax, provides important updates on the company's pipeline progress and could influence investor sentiment regarding its drug development programs.